Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

40.52
Delayed Data
As of Dec 15
 0.00 / 0.00%
Today’s Change
29.39
Today|||52-Week Range
45.87
+6.21%
Year-to-Date
Mylan Announces IPR Proceedings for Sanofi's Lantus Patents
Dec 15 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
Dec 08 / Zacks.com - Paid Partner Content
Walt Disney Up in Pre-Market Thursday
Dec 14 / GuruFocus News - Paid Partner Content
Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest
Dec 04 / Zacks.com - Paid Partner Content
Analysts Take Action on Health Care Stocks
Dec 13 / GuruFocus News - Paid Partner Content
Will the Healthcare Landscape Change with the $69B CVS-Aetna Deal?
Dec 04 / Zacks.com - Paid Partner Content
John Paulson Reduces Synergy Pharmaceuticals After Heavy 3rd Quarter Health Care Sell...
Dec 12 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close40.52
Today’s open40.32
Day’s range39.21 - 40.78
Volume11,767,734
Average volume (3 months)6,873,766
Market cap$21.7B
Data as of 4:00pm ET, 12/15/2017

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)-7.12%
Earnings growth (next 5 years)+3.46%
Revenue growth (last year)+17.44%
P/E ratio24.7
Price/Sales1.79
Price/Book1.95

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...0.000.00%
PRGOPerrigo Company PLC0.000.00%
JAZZJazz Pharmaceuticals...0.000.00%
ALNYAlnylam Pharmaceutic...0.000.00%
Data as of 4:02pm ET, 12/15/2017

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)$1.42
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Director
Heather M. Bresch
President &
Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts